Clinical Trials Information
For information about clinical trials using Cephalon products--sponsored by institutions, the US government, and Cephalon--consult the list of links to the National Institute of Health www.clinicaltrials.gov website.
Click on the title of the study to learn about recruitment status, sites, criteria for participation, and contact information.
Cephalon is recruiting patients for clinical trials in the following areas:
Central Nervous System
- Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury
- Study 1 to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
- Study 2 to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
- Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
- Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder
- Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury
Cancer
- Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma
- Study to Evaluate the Efficacy and Safety of Bendamustine in Combination With Ofatumumab in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
- Substudy of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
- Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
- Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer
- Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
- Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
- Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer
- Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors
Pain
Inflammatory Diseases
Heading 5
Sidebar Text area